Multi-target Drug Therapy

PreclinicalSmall molecule

Multi-target Drug Therapy is one of 34 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intrahepatic CholangiocarcinomaActive, not recruiting

Intrahepatic CholangiocarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Intrahepatic Cholangiocarcinoma

#DrugCompanyPhaseTrials

Lenvima

Eisai

Approved

9 2

Alkeran

Paraplatin

Velcade

SShilpa Grover, MD, MPH

Gemzar

11 6

Imfinzi

AstraZeneca

Phase 2

9 7

Eloxatin

Teva

Phase 2

3 8

Beyfortus

BeiGene

Phase 2

3 9

Imjudo

AstraZeneca

Phase 2

2 10

Opdivo

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intrahepatic Cholangiocarcinoma1 trial

TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma

Unknown status·TThe Central Hospital of Lishui City·N/A·NCT05247996·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Multi-target Drug Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Multi-target Drug Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Multi-target Drug Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Central Hospital of Lishui City company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe Central Hospital of Lishui City

Multi-target Drug Therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intrahepatic Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News